| Serial Number | 99605949 |
| Word Mark | ANDEMBRY |
| Filing Date | Wednesday, January 21, 2026 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, March 31, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, April 21, 2026 |
| Goods and Services | Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE |
| Description of Mark | The mark consists of three curved bars, yellow, blue and green, to the left of "ANDEMBRY" in blue. |
| Indication of Colors claimed | The color(s) yellow, blue and green is/are claimed as a feature of the mark. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 21, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | Saturday, November 30, 2024 |
| First Use In Commerce Date | Saturday, November 30, 2024 |
| Party Name | CSL Behring GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 27 - NOT AVAILABLE |
| Address | Marburg D-35041 DE |
| Event Date | Event Description |
| Wednesday, January 21, 2026 | NEW APPLICATION ENTERED |
| Wednesday, January 21, 2026 | APPLICATION FILING RECEIPT MAILED |
| Monday, March 23, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, March 23, 2026 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Monday, March 23, 2026 | ASSIGNED TO EXAMINER |
| Tuesday, March 24, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, March 24, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, March 24, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, March 24, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, March 24, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |